反应详情

This was prepared using the same procedure as for (4-(6-bromo-7-(4-(pyridin-3-ylmethyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)methanamine, but here using tert-butyl 3-(6-bromo-7-(4-(pyridin-3-ylmethyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)benzylcarbamate (70 mg, 0.12 mmol), TFA (0.6 mL) and CH2Cl2 (2 mL). The same purification procedure gave the desired product (49 mg, 84%) as a colourless solid; δH (500 MHz, DMSO-d6) 2.63 (s, br, 4H, piperazine N(CH2)2), 3.63 (s, 2H, NCH2Ar), 3.68 (t, J=4.3 Hz, 4H, piperazine N(CH2)2), 3.84 (s, 2H, CH2NH2), 7.40 (dd, J=7.7, 4.8 Hz, 1H, pyridine H-5), 7.48-7.50 (m, 2H, phenyl H-4 & H-6), 7.80 (dt, J=7.7, 1.7 Hz, 1H, pyridine H-4), 8.02-8.05 (m, 1H, phenyl H-5), 8.18 (s, br, 1H, phenyl H-2), 8.25 (s, 1H, imidazo[4,5-b]pyridine H-5), 8.50 (dd, J=4.8, 1.5 Hz, 1H, pyridine H-6), 8.58 (d, J=1.6 Hz, 1H, pyridine H-2);

1. customThis was prepared
2. customThe same purification procedure